503 related articles for article (PubMed ID: 18212799)
1. Assessing abuse liability during drug development: changing standards and expectations.
Schoedel KA; Sellers EM
Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
[TBL] [Abstract][Full Text] [Related]
2. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
[TBL] [Abstract][Full Text] [Related]
3. Barcelona meeting on clinical testing of drug abuse liability: consensus statement and recommendations.
Br J Addict; 1991 Dec; 86(12):1527-8. PubMed ID: 1786481
[No Abstract] [Full Text] [Related]
4. Biological evaluation of compounds for their physical dependence potential and abuse liability. XI. Drug testing program of the Committee on Problems of Drug Dependence, Inc. (1987).
Jacobson A
NIDA Res Monogr; 1988; 81():466-84. PubMed ID: 2900468
[No Abstract] [Full Text] [Related]
5. Relationship between reinforcing properties and sensory/motor toxicity of CNS depressants; implications for the assessment of abuse liability.
Brady JV; Lukas SE; Hienz RD
NIDA Res Monogr; 1983 Apr; 43():196-202. PubMed ID: 6410252
[No Abstract] [Full Text] [Related]
6. CNS stimulants and the look-alike drugs.
Lake CR; Quirk RS
Psychiatr Clin North Am; 1984 Dec; 7(4):689-701. PubMed ID: 6151645
[TBL] [Abstract][Full Text] [Related]
7. Human abuse liability evaluation of CNS stimulant drugs.
Romach MK; Schoedel KA; Sellers EM
Neuropharmacology; 2014 Dec; 87():81-90. PubMed ID: 24793872
[TBL] [Abstract][Full Text] [Related]
8. [Road safety under psychiatric drug targeting].
Brunnauer A; Laux G
Fortschr Neurol Psychiatr; 2008 Jun; 76(6):366-77. PubMed ID: 18512188
[No Abstract] [Full Text] [Related]
9. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
10. Principles of assessment of abuse liability: US legal framework and regulatory environment.
Rocha BA
Behav Pharmacol; 2013 Sep; 24(5-6):403-9. PubMed ID: 23820327
[TBL] [Abstract][Full Text] [Related]
11. Abuse of benzodiazepines: the problems and the solutions. A report of a Committee of the Institute for Behavior and Health, Inc.
Am J Drug Alcohol Abuse; 1988; 14 Suppl 1():1-69. PubMed ID: 2902782
[TBL] [Abstract][Full Text] [Related]
12. Formulation considerations for the development of medications with abuse potential.
Mansbach RS; Moore RA
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
[TBL] [Abstract][Full Text] [Related]
13. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States.
Calderon SN; Klein M
Neuropharmacology; 2014 Dec; 87():97-103. PubMed ID: 24727212
[TBL] [Abstract][Full Text] [Related]
14. Recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB). Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2005 Jan; 70(2):291-4. PubMed ID: 15630794
[TBL] [Abstract][Full Text] [Related]
15. Human drug abuse liability: testing times ahead.
Camí J
Br J Addict; 1991 Dec; 86(12):1525-6. PubMed ID: 1786479
[No Abstract] [Full Text] [Related]
16. Committee opinion no. 538: nonmedical use of prescription drugs.
Committee on Health Care for Underserved Women, The American College of Obstetricians and Gynecologists
Obstet Gynecol; 2012 Oct; 120(4):977-82. PubMed ID: 22996128
[TBL] [Abstract][Full Text] [Related]
17. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
18. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
Cone EJ
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
[TBL] [Abstract][Full Text] [Related]
19. [Abuse-related adverse drug reactions and abuse deterrent formulations].
Papaseit E; Pérez-Mañá C; Torrens M; Farré M
Med Clin (Barc); 2013 Nov; 141(10):454-8. PubMed ID: 24144061
[No Abstract] [Full Text] [Related]
20. An exploratory study of drug abuse and dependence information in package inserts.
Phipps LB; Balster RL; Slattum PW; Kirkwood CK
J Addict Dis; 2007; 26(2):25-34. PubMed ID: 17594995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
